Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gliclazide→

Gliclazide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
21187-98-4
Molecular formula
C15H21N3O3S
Molecular weight
323.4 g/mol
Drug class
Second-generation sulfonylurea oral antidiabetic
Mechanism of action
Stimulates insulin secretion from pancreatic beta cells by binding the sulfonylurea receptor (SUR1) and closing ATP-sensitive potassium channels, leading to membrane depolarisation, calcium influx and insulin release. It also has reported haemovascular effects.
Indications / reported uses
  • Treatment of type 2 diabetes mellitus in adults when dietary measures, exercise and weight reduction alone are insufficient

Sources: UK SmPC — Gliclazide 40 mg tablets · UK SmPC — Gliclazide 40 mg tablets (alternate product) · UK SmPC — Gliclazide 80 mg tablets · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gliclazide Environmental Risk Assessment (ERA) (the Gliclazide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.